Tempus AI (TEM) Stock Price, News & Analysis

Company Overview

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data. Through proprietary bioinformatics pipelines and AI algorithms, Tempus delivers interpretive reports that highlight actionable mutations, potential biomarkers and relevant clinical trials. In addition to oncology applications, the platform is designed to support research across immuno-oncology, hematology and other therapeutic areas, helping pharmaceutical and biotechnology partners accelerate drug discovery and development.

Founded in 2015 by entrepreneur Eric Lefkofsky, who serves as chairman and chief executive officer, Tempus is headquartered in Chicago with additional laboratory and research facilities across the United States. Under Lefkofsky’s leadership, the company has grown its dataset to include hundreds of thousands of de-identified patient records, establishing one of the industry’s largest repositories of real-world evidence. Tempus collaborates with academic medical centers, regional health systems and community oncology practices to expand access to genomic testing and AI-enabled insights.

Through strategic partnerships and a continuous investment in technology, Tempus aims to democratize access to precision medicine and improve patient outcomes on a global scale. Its services are utilized by healthcare providers seeking to tailor treatment plans, by researchers conducting retrospective analyses, and by life sciences organizations pursuing novel therapeutic targets, underscoring Tempus’s role at the intersection of data science and clinical innovation.

Key Stats

• Today's Range: $72.23 to $76.39
• 50-Day Range: $54.89 to $80.52
• 52-Week Range: $31.36 to $91.45
• Volume: 7.65 million shs
• Average Volume: 12.00 million shs
• Market Capitalization: $13.18 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $67.64
• Consensus Rating: Moderate Buy

Tempus AI Stock Analysis - MarketRank™

Tempus AI scored higher than 37% of companies evaluated by MarketBeat, and ranked 747th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tempus AI has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tempus AI has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tempus AI are expected to grow in the coming year, from ($6.15) to ($1.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tempus AI is -63.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tempus AI is -63.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tempus AI has a P/B Ratio of 42.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

25.65% of the float of Tempus AI has been sold short.

Short Interest Ratio / Days to Cover

Tempus AI has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempus AI has recently decreased by 3.38%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tempus AI does not currently pay a dividend.

Dividend Growth

Tempus AI does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

25.65% of the float of Tempus AI has been sold short.

Short Interest Ratio / Days to Cover

Tempus AI has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempus AI has recently decreased by 3.38%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.73

News Sentiment

Tempus AI has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Tempus AI this week, compared to 36 articles on an average week.

Search Interest

126 people have searched for TEM on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

57 people have added Tempus AI to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tempus AI insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,660,938.00 in company stock.

Percentage Held by Insiders

26.27% of the stock of Tempus AI is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 24.22% of the stock of Tempus AI is held by institutions.

TEM Stock Analysis - Frequently Asked Questions

How have TEM shares performed this year?

Tempus AI's stock was trading at $33.76 on January 1st, 2025. Since then, TEM shares have increased by 124.7% and is now trading at $75.86.

How were Tempus AI's earnings last quarter?

Tempus AI, Inc. (NASDAQ:TEM) released its quarterly earnings data on Friday, August, 8th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. The firm's revenue for the quarter was up 89.5% compared to the same quarter last year.
Read the conference call transcript.

When did Tempus AI IPO?

Tempus AI (TEM) raised $411 million in an IPO on Friday, June 14th 2024. The company issued 11,100,000 shares at a price of $37.00 per share.

Who are Tempus AI's major shareholders?

Top institutional investors of Tempus AI include ARK Investment Management LLC (4.29%), Sumitomo Mitsui Trust Group Inc. (2.24%), Nikko Asset Management Americas Inc. (2.24%) and Franklin Resources Inc. (0.84%). Insiders that own company stock include Bradley A Keywell, Eric P Lefkofsky, Ryan Fukushima, James William Rogers, Andrew Polovin, Erik Phelps, Ryan M Bartolucci, Nadja West, Jennifer A Doudna and David R Epstein.
View institutional ownership trends.

How do I buy shares of Tempus AI?

Shares of TEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tempus AI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tempus AI investors own include AST SpaceMobile (ASTS), NVIDIA (NVDA), Broadcom (AVGO), Micron Technology (MU), Recursion Pharmaceuticals (RXRX), Genius Sports (GENI) and Super Micro Computer (SMCI).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 8/30/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:TEM
• Previous Symbol: NASDAQ:TEM
• CIK: 1717115
• Web: www.tempus.com
• Phone: 800-976-5448
• Fax: N/A
• Employees: 2,400
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tempus AI: $67.64
• High Price Target: $85.00
• Low Price Target: $52.00
• Potential Upside/Downside: -10.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$705.81 million
• Net Margins: -20.98%
• Pretax Margin: -24.93%
• Return on Equity: -122.86%
• Return on Assets: -18.09%

Debt

• Debt-to-Equity Ratio: 2.58
• Current Ratio: 1.54
• Quick Ratio: 1.43

Sales & Book Value

• Annual Sales: $951.98 million
• Price / Sales: 13.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.78 per share
• Price / Book: 42.62

Miscellaneous

• Outstanding Shares: 173,728,000
• Free Float: 128,090,000
• Market Cap: $13.18 billion
• Optionable: N/A
• Beta: 4.98